Geracimos Rassias

Title: Geracimos Rassias: Innovator in Neurological Treatments

Introduction

Geracimos Rassias is a notable inventor based in Stevenage, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target neurological and psychiatric conditions. His work is characterized by a focus on innovative solutions that address cognitive impairments and sleep disorders.

Latest Patents

Rassias holds a patent for a piperazine derivative that exhibits affinity for the histamine H3 receptor. The patent, titled "Piperazine derivative having affinity for the histamine H3 receptor," describes a compound known as 1-(1-methylethyl)-4-{[4-(tetrahydro-2H-pyran-4-yloxy)phenyl]carbonyl}piperazine, along with its pharmaceutically acceptable salt, particularly the hydrochloride salt. This invention is aimed at treating or preventing neurological or psychiatric diseases, such as cognitive impairment, fatigue, or sleep disorders in mammals, including humans. The compound acts as an antagonist and/or inverse agonist of the histamine H3 receptor.

Career Highlights

Geracimos Rassias is associated with Glaxo Group Limited, where he has been instrumental in advancing research and development in the pharmaceutical sector. His innovative approach has led to the creation of valuable therapeutic options for patients suffering from various neurological conditions.

Collaborations

Rassias has collaborated with esteemed colleagues, including Desmond John Best and Sing Yeung Mak. These partnerships have fostered a collaborative environment that enhances the research and development process, leading to groundbreaking advancements in the field.

Conclusion

Geracimos Rassias is a prominent figure in the pharmaceutical industry, recognized for his innovative contributions to neurological treatments. His patent for a piperazine derivative showcases his commitment to improving patient outcomes through scientific research and collaboration.